Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.57 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.51 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.51 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.49 |
| ▸ | NMT1 | P30419 | 12/20 | 0.48 |
| ▸ | METAP2 | P50579 | 1/20 | 0.46 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.45 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.45 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.45 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10198619 | 0.83 | TLR9 (0.50) | TLR9TLR8TLR7METAP2 | |
| SCHEMBL13978113 | 0.82 | NMT1 (0.43) | DYRK1ATLR9TLR8TLR7NMT1 | |
| SCHEMBL15274971 | 0.79 | TLR9 (0.47) | TLR9TLR8TLR7METAP2 | |
| SCHEMBL29157425 | 0.78 | DYRK1A (0.61) | DYRK1AADRB1NMT1 | |
| SCHEMBL10198628 | 0.78 | PIM1 (0.50) | ADRB1 | |
| SCHEMBL3442456 | 0.78 | DYRK1A (0.64) | DYRK1AADRB1NMT1PLD1 | |
| SCHEMBL21594 | 0.74 | HTR7 (0.65) | TLR9TLR8TLR7ADRB1 | |
| SCHEMBL15274976 | 0.73 | PIM1 (0.46) | TLR9TLR8TLR7ADRB1 | |
| SCHEMBL38664957 | 0.73 | DYRK1A (0.55) | DYRK1ATLR9TLR8TLR7ADRB1 | |
| SCHEMBL29534298 | 0.73 | NMT1 (0.60) | DYRK1ANMT1PRKD3PRKD1PRKD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10603294-B2 | Compounds for use in treatment of mucositis | INNOVATION PHARMACEUTICALS INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190282521-A1 | Compounds For Use In Treatment Of Mucositis | POLYMEDIX, INC. | 2019-09-19 | — | — | US | disclosed |
| US-10206894-B2 | Compounds for use in treatment of mucositis | INNOVATION PHARMACEUTICALS INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180064664-A1 | Compounds For Use In Treatment of Mucositis | POLYMEDIX, INC. | 2018-03-08 | — | — | US | disclosed |
| US-20180064664-A1 | Compounds For Use In Treatment of Mucositis | POLYMEDIX, INC. | 2018-03-08 | — | — | US | disclosed |
| US-9795575-B2 | Compounds for use in treatment of mucositis | INNOVATION PHARMACEUTICALS INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9795575-B2 | Compounds for use in treatment of mucositis | INNOVATION PHARMACEUTICALS INC. (US) | 2017-10-24 | — | — | US | disclosed |
| EP-2709619-B1 | COMPOUNDS FOR USE IN TREATMENT OF MUCOSITIS | CELLCEUTIX CORP (US) | 2017-10-11 | — | — | EP | disclosed |
| US-20170224640-A1 | Compounds For Use In Treatment Of Mucositis | INNOVATION PHARMACEUTICALS INC. | 2017-08-10 | — | — | US | disclosed |
| US-20170224640-A1 | Compounds For Use In Treatment Of Mucositis | INNOVATION PHARMACEUTICALS INC. | 2017-08-10 | — | — | US | disclosed |
| US-20120258141-A9 | Methods Of Immune Modulation | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120258141-A9 | Methods Of Immune Modulation | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120115877-A1 | Facially Amphiphilic Compounds, Compositions, And Uses Thereof In Treating Cancer | POLYMEDIX, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115877-A1 | Facially Amphiphilic Compounds, Compositions, And Uses Thereof In Treating Cancer | POLYMEDIX, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120039945-A1 | Methods Of Immune Modulation | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120039945-A1 | Methods Of Immune Modulation | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-02-16 | — | — | US | disclosed |
| WO-2012006315-A2 | METHODS OF IMMUNE MODULATION | POLYMEDIX, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
| US-20100081665-A1 | Anti-Malarial Compounds | CELLCEUTIX CORPORATION | 2010-04-01 | — | — | US | disclosed |
| US-20100081665-A1 | Anti-Malarial Compounds | CELLCEUTIX CORPORATION | 2010-04-01 | — | — | US | disclosed |
| WO-2010014573-A1 | ANTI-MALARIAL COMPOUNDS | POLYMEDIX, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170224640-A1 | Compounds For Use In Treatment Of Mucositis | MUC1, FUT6, MMP8 | DYRK1A 4829/4885TLR9 12/4885TLR8 19/4885 |
| US-10603294-B2 | Compounds for use in treatment of mucositis | MUC1, FUT6, MMP8 | DYRK1A 4829/4885TLR9 12/4885TLR8 19/4885 |
| US-20120115877-A1 | Facially Amphiphilic Compounds, Compositions, And Uses Thereof In Treating Cancer | LIPA, ABHD16A, SGMS1 | DYRK1A 4415/4885TLR9 581/4885TLR8 1062/4885 |
| US-20120258141-A9 | Methods Of Immune Modulation | IFNG, CD14, TLR3 | DYRK1A 4504/4885TLR9 11/4885TLR8 39/4885 |
| US-20120039945-A1 | Methods Of Immune Modulation | IFNG, CD14, TLR3 | DYRK1A 4504/4885TLR9 11/4885TLR8 39/4885 |
| US-10206894-B2 | Compounds for use in treatment of mucositis | MUC1, FUT6, SI | DYRK1A 4739/4885TLR9 27/4885TLR8 32/4885 |
| US-20100081665-A1 | Anti-Malarial Compounds | AADAC, ME2, HTRA2 | DYRK1A 3560/4885TLR9 2121/4885TLR8 802/4885 |
| US-20190282521-A1 | Compounds For Use In Treatment Of Mucositis | MUC1, FUT6, MMP8 | DYRK1A 4829/4885TLR9 12/4885TLR8 19/4885 |
| US-20180064664-A1 | Compounds For Use In Treatment of Mucositis | MUC1, FUT6, SI | DYRK1A 4739/4885TLR9 27/4885TLR8 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.